IMRN
Immuron Limited Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website immuron.com.au
- Employees(FY) 6
- ISIN US45254U1016
Performance
-3.93%
1W
-3.33%
1M
+26.6%
3M
+28.18%
6M
+23.73%
YTD
+1.31%
1Y
Profile
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis of IMRN 2024-05-10
Overview:
In analyzing the technical indicators for IMRN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2023-06-29 18:00
Immuron Chairman Transition(Yahoo Finance)
- 2023-06-21 18:00
Immuron Business Update: Letter to Shareholders(Yahoo Finance)
- 2023-05-29 18:00
Immuron Initiates Recruitment of Travelan® Clinical Study(Yahoo Finance)
- 2023-05-15 19:30
- 2023-05-08 01:11
- 2023-05-07 18:00
- 2023-05-01 18:00
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps(Yahoo Finance)
- 2023-04-18 18:00
Immuron Q3 FY23 Business Update Presentation(Yahoo Finance)
- 2023-04-10 18:00
Q3 FY23 Business Update Webinar Notification(Yahoo Finance)
- 2023-04-05 18:00
Immuron Q3 Sales reach 150% of 1H Sales(Yahoo Finance)
- 2023-02-14 17:00
Immuron CEO, Steven Lydeamore to host an investor webinar(Yahoo Finance)
- 2023-01-24 17:00
- 2023-01-17 16:00
- 2023-01-16 18:10
- 2022-12-22 17:00
Immuron Receives FDA Approval for Travelan IND Application(Yahoo Finance)
- 2022-12-04 17:00
Immuron Submits IND Application To FDA for Travelan(Yahoo Finance)
- 2022-11-15 18:00
- 2022-10-25 18:00
Immuron CEO, Steven Lydeamore to present at AusBioInvest(Yahoo Finance)
- 2022-10-12 22:28
- 2022-10-12 18:00
- 2022-10-03 18:00
- 2022-08-28 19:00
Immuron CEO, Steven Lydeamore, to host an investor webinar(Yahoo Finance)
- 2022-08-18 19:23
- 2022-08-18 18:00
Immuron Update on IMM-124E SARS-CoV-2 Research(Yahoo Finance)
- 2022-07-25 19:07
- 2022-07-25 18:00
- 2022-07-10 18:00
- 2022-07-06 18:00
- 2022-05-10 18:00
- 2022-05-08 18:00